Role of Biomarkers in Management of Prostate Cancer

Download Report

Transcript Role of Biomarkers in Management of Prostate Cancer

Role of Biomarkers in
Management of Prostate
Cancer
Dr. Angela Amayo
Specialist Pathologist
13th April 2012
Outline
Review
• Performance characteristics of PSA
markers
• Limitations of PSA
• Guidelines for clinical utility of PSA in
screening and treatment monitoring.
Tumour Biomarkers
• Substances usually found in body fluids.
• Used to determine the presence of
tumours.
• Are produced by
- tumour cells, or
- host cells in response to presence of
tumour
Prostate Specific Antigen (PSA)
• A protease enzyme produced by prostatic
epithelial cells.
• Circulates in blood in free form or bound to
α1- antichymotrypsin.
• Serum reference values < 2ug/L
• Elevations found in prostatitis, BPH and
Prostate cancer.
• PSA use reported to contribute greatly to
early Ca prostate diagnosis.
Criteria for assessing usefulness of
tumour biomarkers:• High sensitivity – detectable when only few
cancer cells present.
Sensitivity = TPos
TPos+ FNeg
• High specificity – not detectable in healthy
individuals or in non-malignant disease.
Specificity = TNeg
TNeg + FPos.
Clinical Utility of PSA
• Screening – Widespread use
• Diagnosis – Limited use
• Prognosis – Limited usefulness.
• Treatment Monitoring - Indicated
PSA Performance characteristics in
screening
At cut-off of 4 ug/L:
- Sensitivity 78%
- Specificity 33%.
Causes of low specificity:
• Elevations in non malignant situations
BPH
Prostatitis
Prostate surgical procedures
Approaches to increase PSA specificity
1. Use of free PSA
• For PSA 4-10ug/L
• Estimate percent free PSA.
• Low % free PSA associated with higher
likelihood of cancer.
% Free PSA
Cancer Risk
> 25%
<10%
< 10%
56%
Approaches to increase PSA specificity
2. Use of age dependent reference
values.
• Improves detection of cancer in younger
adults.
Age
Reference values
40 – 49 yrs
0 – 2.5 ug/L
50 – 59 yrs
0 – 3.5ug/L
60 – 69 yrs
0 – 4.5ug/L
Approaches to increase PSA specificity
3. Use of PSA dynamics
• Includes PSA velocity and PSA doubling
time. Based on annual PSA testing.
• Measures rate of PSA increase over time.
• Highest increase rate in cancer.
• In PSA >4, increase >0.75ug/L/yr
significant
• In PSA <4, increase > 0.5ug/L/yr
significant.
Purpose of PSA screening
To identify those with high cancer risk
who should undergo diagnostic biopsy.
PSA Screening approaches
Authority
Recommendations
American Cancer Society
Annual Screening
From 50 – 76 years
Afr Ame from 45 years
American College of
Physicians
Above with proviso –
inform clients of risks and
benefits. Clients make
informed choice.
Kenya
?
Use of PSA in treatment monitoring
1. Assessment of completeness of
surgery
• Following prostatectomy, PSA levels
should be < 2ug/L.
• PSA should be measured after 6 weeks
(allow clearance of PSA released during
surgery).
• Persistent elevations may suggest residual
tumour or metastatic disease
Use of PSA in treatment monitoring
2. Active surveillance or follow up after
surgery/ radiation
• Important use of tumour biomarker
• Evaluates success of therapy
• Aid in early detection of recurrence
Biomarkers in treatment monitoring
• Decrease in marker level to normal
indicates effective treatment.
• Persistent elevation of marker indicates
residual disease or metastases.
• Renewed increase after period of normal
indicates recurrence of tumour.
• Requires serial estimations of biomarkers.
• Method used for testing important for
interpretation of serial results.
• Same analytical method should be used.
Interpretation of biomarker during
treatment monitoring
• No change- Marker does not fall to <50%
of pretreatment values.
• Improvement- Marker falls to < 50% of
pretreatment values.
• Response – Marker falls to <10%
pretreatment values.
• Complete response- Marker falls to normal
reference value.
SUMMARY
• PSA is an organ specific tumour
biomarker.
• Specificity of PSA for Ca Prostate is low
• Knowledge of the performance
characteristics is important.
• Approaches can be used to improve
specificity.
• Useful role for PSA in treatment
monitoring.
• Analytical method used important for
interpretation of results.
Thank You